Ardelyx | ARDX - Interest Expense On Debt


Ardelyx reported $6.58M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 466.77M
Cash and Equivalent USD 90.04M
Cost of Sales USD 14.82M
Current Assets USD 351.57M
Current Liabilities USD 81.72M
Debt USD 206.64M
Dividend Yield -6.39
EBIT USD -12.5M
EBITDA USD -11.87M
Employees 395
EPS Earnings Per Share USD -0.08
Equity Capital and Reserves USD 139.53M
Gross Profit on Sales USD 82.84M
Interest Expense on Debt USD 6.58M
Loan Capital USD 229.21M
Market Capitalization USD 1.52B
Net Income USD -19.08M
Operating Expenses USD 112.06M
Operating Profit USD -14.4M
Ordinary Share Capital USD 240.77M
Pre-Tax Profit USD -19.08M
Sales Revenues USD 97.66M
Selling and Administration Expenses USD 83.99M
Stock USD 22.28M
Trade Creditors USD 21.68M
Trade Debtors USD 62.55M

Interest Expense On Debt Change Date
Abbott USD 50M 1000K Jun/2025
Amgen USD 694M 29M Jun/2025
Ardelyx USD 6.58M 2.61M Jun/2025
Corcept Therapeutics USD 6M 6M Jun/2024
Life Technologies USD 0 0 Sep/2024
Sanofi EUR 62M 4.11M Jun/2025
TG Therapeutics USD 6.72M 4.12M Jun/2025
United Therapeutics USD 7.3M 1.2M Jun/2025